Published in Mol Immunol on March 11, 2010
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Helios expression is a marker of T cell activation and proliferation. PLoS One (2011) 2.55
Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection. Immunity (2014) 1.68
FOXO transcription factors throughout T cell biology. Nat Rev Immunol (2012) 1.60
Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol (2014) 1.53
Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One (2012) 1.52
Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol (2013) 1.13
Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression. PLoS One (2011) 1.06
Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol (2013) 1.06
Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol (2012) 1.06
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol (2013) 1.03
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res (2013) 1.02
CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol (2011) 1.02
Nature and nurture in Foxp3(+) regulatory T cell development, stability, and function. Hum Immunol (2011) 1.02
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget (2015) 0.99
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells. J Immunol (2015) 0.96
Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naïve mice. Sci Rep (2015) 0.96
Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol (2012) 0.95
Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model. J Immunol (2011) 0.94
Differential control of Helios(+/-) Treg development by monocyte subsets through disparate inflammatory cytokines. Blood (2013) 0.92
Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease. Front Immunol (2015) 0.91
Transcription factors involved in the regulation of natural killer cell development and function: an update. Front Immunol (2012) 0.91
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol (2013) 0.91
Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection. J Immunol (2015) 0.89
Differences in Expression Level of Helios and Neuropilin-1 Do Not Distinguish Thymus-Derived from Extrathymically-Induced CD4+Foxp3+ Regulatory T Cells. PLoS One (2015) 0.87
Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. Immunology (2010) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Clinical significance of expanded Foxp3+ Helios- regulatory T cells in patients with non-small cell lung cancer. Int J Oncol (2015) 0.85
Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol Immunother (2012) 0.84
T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology (2013) 0.82
mTOR signaling, Tregs and immune modulation. Immunotherapy (2014) 0.82
Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes. Cell Mol Immunol (2011) 0.82
Characterization of the Treg Response in the Hepatitis B Virus Hydrodynamic Injection Mouse Model. PLoS One (2016) 0.80
Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants. J Clin Immunol (2012) 0.80
CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo. J Virol (2016) 0.78
Expression of Helios in gastric tumor cells predicts better survival in gastric cancer patients. J Cancer Res Clin Oncol (2016) 0.78
T regulatory cells in B-cell malignancy - tumour support or kiss of death? Immunology (2012) 0.78
Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance. Transplantation (2014) 0.78
The importance of the nurse cells and regulatory cells in the control of T lymphocyte responses. Biomed Res Int (2012) 0.78
Protein phosphatase 4 is an essential positive regulator for Treg development, function, and protective gut immunity. Cell Biosci (2014) 0.77
IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint. Clin Exp Immunol (2015) 0.76
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol (2014) 0.76
The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells. PLoS One (2013) 0.76
Intratumoral FoxP3(+)Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol (2017) 0.75
Low-dose oral cholecalciferol is associated with higher numbers of Helios(+) and total Tregs than oral calcitriol in renal allograft recipients: an observational study. BMC Pharmacol Toxicol (2016) 0.75
Alternative Splice Variants Modulates Dominant-Negative Function of Helios in T-Cell Leukemia. PLoS One (2016) 0.75
The Ikaros family of zinc-finger proteins. Acta Pharm Sin B (2016) 0.75
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol (2016) 0.75
Association of peripheral NK cell counts with Helios(+) IFN-γ(-) Tregs in patients with good long-term renal allograft function. Clin Exp Immunol (2017) 0.75
Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft function. PLoS One (2017) 0.75
Mapping eQTLs with RNA-Seq Reveals Novel Susceptibility Genes, Non-Coding RNAs, and Alternative-Splicing Events in Systemic Lupus Erythematosus. Hum Mol Genet (2017) 0.75
CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget (2015) 0.75
Regulatory T cells: Tolerance Induction in Solid Organ Transplantation. Clin Exp Immunol (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2007) 6.22
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity (2009) 6.11
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol (2007) 5.45
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol (2005) 5.43
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature (2007) 5.14
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol (2007) 3.82
Regulatory T cells and intestinal homeostasis. Immunol Rev (2005) 3.82
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol (2006) 2.93
Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol (2006) 2.56
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev (1998) 2.37
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol (2003) 1.96
Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol (1998) 1.92
Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes. J Biol Chem (2007) 1.76
Role of regulatory T cells in human diseases. J Allergy Clin Immunol (2005) 1.52
Helios deficiency has minimal impact on T cell development and function. J Immunol (2009) 1.50
Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol (2005) 1.35
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
Expression of a non-DNA-binding isoform of Helios induces T-cell lymphoma in mice. Blood (2006) 0.99
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest (2013) 1.94
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol (2005) 1.78
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol (2011) 1.58
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54